Summary of Conference Call Company Overview - The company discussed is Integer, which operates in the cardiovascular medical device industry. The transition of CEO from Joe to Peyman is highlighted, with Peyman having been part of the leadership team since early 2018 [1][2]. Core Strategies and Goals - Integer's strategy focuses on four targeted growth markets: electrophysiology, structural heart, neurovascular, and neuromodulation. The company aims to grow at 200 basis points above market growth rates [5][10]. - The company has established growth teams to refine and execute strategies in these markets, leading to a 270% increase in development work since 2017 [10][11]. - Profitability targets are set to grow at twice the rate of sales growth, supported by the Integer Production System [6][51]. Market Dynamics - The company is positioned to benefit from innovation in the industry, focusing on unmet patient needs and ensuring integration into customer programs [8][9]. - The electrophysiology market is projected to double in size to $20 billion over the next five years, providing significant growth opportunities [28][31]. - Integer's vertical integration allows it to manufacture a larger portion of devices, reducing the need for multiple suppliers and enhancing competitive advantage [32]. Financial Performance - The company reported an 11% organic growth rate in its C and D segments, with expectations for mid-teens growth in the CNV business [21][22]. - The backlog is currently at $800 million, expected to decrease to around $600 million by year-end due to the exit of the Portal Medical business and improved manufacturing capacity [56][57]. Acquisitions and Growth - Integer's acquisition strategy focuses on tuck-in acquisitions that enhance critical capabilities in targeted growth markets [16][20]. - The company has fostered relationships with smaller, founder-led businesses, positioning itself as a credible partner for growth [19][20]. Emerging Markets and Innovations - Neuromodulation is identified as a key area for growth, with a 40% increase in the number of customers and programs since 2020 [43][45]. - The company is actively involved in the development of therapies for ischemic stroke and intracranial aneurysm through its acquisition of Inuraco [40][41]. Operational Efficiency - Integer emphasizes continuous improvement in manufacturing processes, aiming to enhance efficiency and reduce waste [54][55]. - The company has a strong manufacturing footprint that aligns with customer needs for design and development [55]. Conclusion - Integer is well-positioned for sustained growth through its strategic focus on innovation, targeted markets, and operational efficiencies, with a clear roadmap for future profitability and market expansion [6][51].

Investors with an interest in Medical - Instruments stocks have likely encountered both Integer (ITGR) and Penumbra (PEN) . But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out.The best way to find great value stocks is to pair a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system. The proven Zacks Rank puts an emphasis on earnings estimates and estimate revisions, while our Style Scores work to identify sto ...

PLANO, Texas, June 03, 2025 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE: ITGR), a leading medical device contract development and manufacturing organization, today announced participation in the 2025 Truist Securities MedTech Conference, to be held June 17, 2025, in Boston. Members of the Integer executive leadership team will participate in a fireside chat on Tuesday, June 17, at 10:40 a.m. ET. A live webcast of the presentation will be accessible under “News & Events” on the Investor Relations ...

Investors interested in Medical - Instruments stocks are likely familiar with Integer (ITGR) and SONOVA HOLDING (SONVY) . But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look.Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank. The Zacks Rank is a proven strategy that targets companies with positive ea ...

Summary of Integer Holdings Conference Call Company Overview - **Company**: Integer Holdings - **Industry**: Medical Technology (Med Tech) Key Points and Arguments CEO Transition - Joe Dizik, the current CEO, is transitioning to retirement, with Peyman Kales set to take over later this year [5][7] - The transition is seen as timely, with the company in a strong position, having met strategic objectives set in 2018 [7][8] Financial Performance and Guidance - Integer Holdings reported sales growth of 8% to 10% for the year, with organic growth of 6% to 8% [8] - Net income is expected to rise by 19% to 26%, and earnings per share guidance is set at 16% to 23% [8] - Q1 results showed 6% organic growth, with a reported 17% growth in the cardiovascular segment [19][20] Strategic Focus and Market Position - The company has a strong presence in growth markets, particularly in electrophysiology (EP) and pulsed field ablation (PFA) [15][16] - The pipeline of opportunities has increased by 270%, with 80% focused on growth markets [16] - Integer Holdings aims to maintain a debt leverage ratio of 2.5 to 3.5, which is considered prudent for the industry [8][17] Operational Insights - Operating income grew by 14% in Q1, indicating strong operational leverage [28] - The company expects to see improvements in gross margins and operational efficiencies, particularly in R&D [30][32] - Integer Holdings is exiting the portable medical business, which is expected to decline by $29 million year-over-year, offset by $59 million from acquisitions [26][27] Tariff and Supply Chain Management - The expected tariff impact for 2025 is estimated to be between $1 million to $5 million, due to the company's supply chain positioning [40][41] - Integer Holdings has a global manufacturing footprint, which mitigates tariff risks [46][47] Growth Areas - The cardiovascular business has reached $1 billion and is growing double digits, driven by acquisitions and market expansion [55] - Emerging markets such as neuromodulation and cardiac rhythm management are expected to drive future growth, with a projected growth rate of 15% to 20% [66][67] Portfolio Management - Integer Holdings has divested non-core assets to focus on high-potential markets, particularly in cardiovascular and neuromodulation [68][70] - The company emphasizes the importance of cash generation from established segments to fund growth in faster-growing areas [70][72] Additional Important Insights - The leadership transition is expected to be smooth, with Peyman Kales being well-prepared to take over [11][15] - The company maintains strong relationships with customers, which aids in navigating pricing pressures and cost management [52][54] - Integer Holdings is committed to a long-term growth strategy, focusing on innovation and market leadership in targeted segments [17][60]

Investors interested in Medical - Instruments stocks are likely familiar with Integer (ITGR) and SONOVA HOLDING (SONVY) . But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look.Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank. The Zacks Rank favors stocks with strong earnings estimate revision trends, ...

Shares of Integer (ITGR) have gained 3.2% over the past four weeks to close the last trading session at $116.55, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $150.38 indicates a potential upside of 29%.The mean estimate comprises eight short-term price targets with a standard deviation of $6.95. While the lowest estimate of $140 indicates a 20.1% increase from the current pri ...

PLANO, Texas, April 29, 2025 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE: ITGR), a leading medical device contract development and manufacturing organization (CDMO), today announced participation in the 2025 Bank of America Securities Health Care Conference, to be held May 13-15, 2025, in Las Vegas. Members of the Integer executive leadership team will participate in a fireside chat on Wednesday, May 14, at 10:00 a.m. PT. Integer Holdings Corporation (NYSE: ITGR) is one of the largest medical dev ...

Integer Holdings Corporation (ITGR) delivered adjusted earnings per share (EPS) of $1.31 in the first quarter of 2025, which improved 14.9% year over year. The figure topped the Zacks Consensus Estimate by 3.2%.Find the latest EPS estimates and surprises on Zacks Earnings Calendar.The adjustments include expenses related to the amortization of intangible assets and restructuring and restructuring-related charges, among others.GAAP loss per share for the quarter was 66 cents, against EPS of 59 cents in the p ...

Integer (ITGR) Q1 2025 Earnings Call April 25, 2025 12:52 AM ET Company Participants Sanjiv Arora - SVP, Strategy, Business Development and IRJoseph Dziedzic - President & CEOPayman Khales - COODiron Smith - Executive VP & CFORichard Newitter - Managing DirectorNathan Treybeck - Equity Research Vice PresidentAndrew Cooper - VP - Equity ResearchJoanne Wuensch. - Managing DirectorSuraj Kalia - Managing Director Conference Call Participants Brett Fishbin - Vice President & Equity Research AnalystCraig Bijou - ...